Brief: Oryzon To Address FDA Feedback Regarding Phase III Of Vafidemstat And Resubmit Protocol
17/10/2025 17:07
Oct 17 (Reuters) - Oryzon Genomics SA ORY.MC: RECEIVES COMMENTS FROM FDA IN RESPONSE TO PHASE III PROTOCOL SUBMITTED FOR BORDERLINE PERSONALITY DISORDER COMPANY TO ADDRESS FEEDBACK AND RESUBMIT REVISED PROTOCOL Source text: nCNM1tFd8m Further company coverage: ORY.MC (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com;))
Recent news on ORYZON Genomics SA
See all newsBrief: Oryzon Gets New Patent Grants For Vafidemstat In Four Countries
Brief: Oryzon Gets EMA Approval To Start Phase II Study Of Vafidemstat For PMS Treatment
Spanish stocks - Factors to watch on Aug 31
Brief: Oryzon Gets U.S. Patent Allowance For Iadademstat And Gilteritinib Drug Combo Application
Spanish stocks - Factors to watch on July 28